Home
Antifolate Drugs in Cancer Therapy
Barnes and Noble
Loading Inventory...
Antifolate Drugs in Cancer Therapy
Current price: $219.99
Barnes and Noble
Antifolate Drugs in Cancer Therapy
Current price: $219.99
Loading Inventory...
Size: OS
*Product information may vary - to confirm product availability, pricing, shipping and return information please contact Barnes and Noble
In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs. The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors,
5-fluorouracil, and the new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, folate and antifolate transport mechanisms, polyglutamation, resistance, and drug combinations, as well as pharmacogenomics, pharmacodynamics, regulation of gene expression, and mechanisms of cell death.
The wide and progressive scope of Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research, and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics.
5-fluorouracil, and the new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, folate and antifolate transport mechanisms, polyglutamation, resistance, and drug combinations, as well as pharmacogenomics, pharmacodynamics, regulation of gene expression, and mechanisms of cell death.
The wide and progressive scope of Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research, and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics.
In Antifolate Drugs in Cancer Therapy, Ann Jackman and a panel of highly regarded researchers comprehensively review the current status of novel antifolates, an important class of anticancer drugs. The distinguished contributors discuss the preclinical and clinical pharmacology of methotrexate, other dihydrofolate reductase inhibitors,
5-fluorouracil, and the new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, folate and antifolate transport mechanisms, polyglutamation, resistance, and drug combinations, as well as pharmacogenomics, pharmacodynamics, regulation of gene expression, and mechanisms of cell death.
The wide and progressive scope of Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research, and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics.
5-fluorouracil, and the new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide formyltransferase inhibitors. In addition, they review in depth the modulation of antifolate drugs, folate and antifolate transport mechanisms, polyglutamation, resistance, and drug combinations, as well as pharmacogenomics, pharmacodynamics, regulation of gene expression, and mechanisms of cell death.
The wide and progressive scope of Antifolate Drugs in Cancer Therapy provides entré to exciting new avenues for future research, and constitutes a new standard reference for all basic scientists and clinicians engaged in cancer therapeutics.
You May Also Like
More About Barnes and Noble at The Summit
With an excellent depth of book selection, competitive discounting of bestsellers, and comfortable settings, Barnes & Noble is an excellent place to browse for your next book.
Store Info
